Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Sep;25(6):860-867.
doi: 10.1016/j.pan.2025.08.006. Epub 2025 Aug 9.

Endoscopic ultrasound-guided celiac plexus block for painful chronic pancreatitis: A systematic review and meta-analysis

Collaborators, Affiliations
Free article
Meta-Analysis

Endoscopic ultrasound-guided celiac plexus block for painful chronic pancreatitis: A systematic review and meta-analysis

Jorge D Machicado et al. Pancreatology. 2025 Sep.
Free article

Abstract

Background: The efficacy of endoscopic ultrasound-guided celiac plexus block (EUS-CPB) for treatment of pain in chronic pancreatitis (CP) is unclear. Therefore, we aimed to assess this outcome using a systematic review and meta-analysis.

Methods: We conducted a comprehensive search of MEDLINE, EMBASE, and Cochrane Central for evaluating the efficacy of EUS-CPB for pain in CP. We evaluated: A) overall efficacy of EUS-CPB (defined as proportion of patients with any pain relief); B) duration of pain relief; C) efficacy of EUS-CPB at 4, 8, 12, and 26 weeks post-procedurally; and D) adverse events. A proportional meta-analysis was performed using the logit transformation. Outcomes were pooled using a random-effects model.

Results: 11 studies encompassing 729 patients met inclusion and exclusion criteria. The overall efficacy of EUS-CPB was 53% (95% CI 39-67%, I2 = 91%). The mean duration of pain relief was 81 days (95% CI 30-217, I2 = 96%). The efficacy of EUS-CPB at 4 weeks was 52% (95% CI 22-81%, I2 = 90%), at 8 weeks was 57% (95% CI 48-66%, I2 = 0%), at 12 weeks was 19% (95% CI 12-27%, I2 = 68%), and at 26 weeks was 3% (95% CI 1-8%, I2 = 0%). The prevalence of adverse events was 8% (95% CI 4-15%, I2 = 67%).

Conclusions: EUS-CPB provides pain relief in 53% of patients with painful CP and the effect lasts on average for 3 months. A sham-controlled clinical trial is needed to determine the analgesic efficacy of EUS-CPB for pain in CP.

PubMed Disclaimer

Conflict of interest statement

Disclosures and conflicts of interest Jorge D. Machicado has served in an advisory board of Amgen LCM. Ji Young Bang serves as a consultant for Olympus and Boston Scientific. Shyam Varadarajulu serves as a consultant for Olympus, Boston Scientific, and Medtronic. The remaining authors have no conflicts of interest to disclose.

LinkOut - more resources